Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Apeiron Therapeutics (Hong Kong) Ltd. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split between 2 distinct art units and involve 2 distinct examiners. This indicates that each of the company's active matters is being handled independently in different technical and personnel environments at the patent office, requiring separate strategies for each application.
MOSELEY II, NELSON B is the busiest examiner, with 1 pending office action. Since there are only 2 pending office actions in total, this examiner is responsible for half of the company's current prosecution workload. Practitioners should note the lack of concentration, as the 2 actions are being reviewed by different people in different art units, which prevents the use of a unified approach across the portfolio.
The distribution of 2 pending office actions across 2 distinct art units suggests that the company's biotechnology technology is being evaluated under different sets of technical standards. For a practitioner, this means that the arguments used for the action with MOSELEY II, NELSON B may not be relevant to the other pending matter. This decentralized structure for a small portfolio requires a high level of attention to the specific details of each individual prosecution.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 1 | 68.0% | +41.5% |
| HAVLIN, ROBERT H | 1 | 51.5% | +28.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | MOSELEY II, NELSON B | — |
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | HAVLIN, ROBERT H | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19539095 | PHARMACEUTICAL COMPOSITION COMPRISING A PRMT5 INHIBITOR AND AN EGFR INHIBITOR | MOSELEY II, NELSON B | 1642 | §103DP | Non-Final OA | — | Pending | Feb 13, 2026 |
| 19539109 | PHARMACEUTICAL COMPOSITION COMPRISING PRMT5 INHIBITOR AND PD-1/PD-L1 INHIBITOR | HAVLIN, ROBERT H | 1626 | §103DP | Final Rejection | — | Pending | Feb 13, 2026 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial